-+ 0.00%
-+ 0.00%
-+ 0.00%

Rhythm Pharmaceuticals Unveils Promising Phase 3 Trial Results for Setmelanotide in Treating Acquired Hypothalamic Obesity at ENDO 2025

Reuters·07/12/2025 22:00:23

Please log in to view news